Castleman Disease: A Population Based Study Using the National Cancer Institute's Surveillance, Epidemiology, and End Results Program

Ahuja, Kripa; Goudar, Ranjit K.

doi:10.1182/blood-2022-160303

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown that synchronous multiple primary malignancies are associated with a significant reduction in overall survival compared to metachronous malignant tumors (29). However, there are also studies showing that overall survival is not different in synchronous / metachronous tumors (17). In our study, no statistical difference was found in terms of overall survival, whether synchronous or metachronous.…”

Section: Castlemancontrasting

confidence: 75%

“…disease is a rare lymphoproliferative disease characterized by hyperinflammation. In a study of 66 Castleman patients, one of the two most common causes of death was malignant cancer (17). In our study, a patient with stage 1 Castleman disease was cured by surgical treatment, and vocal cord squamoze squamous cell carcinoma was diagnosed 2 months after the diagnosis of Castleman.…”

Section: Castlemanmentioning

confidence: 62%

See 1 more Smart Citation

A Single-center Experience of Synchronous and Metachronous Hematologic and Oncologic Tumors

YAVAŞOĞLU,

ÖZDEMİR,

ŞENOL

et al. 2023

Osmangazi̇ Journal of Medicine

View full text Add to dashboard Cite

The incidence of cancer is increasing in the world. With the developments in cancer treatment, the life expectancy of patients is prolonged and the incidence of secondary malignancies is increasing. We retrospetively patients with syncronous / metachronous oncological malignancies accompanying hematological malignancies in a newly established hematology center. Data were obtained from the medical records. Demographic data, treatments and overall survival of the patients were evaluated. Twenty eight (6%) of 433 patients hematological malignancies were included in the study. 12 patients (42.9) were diagnosed with syncronous and 16 (57.1%) patients with metachronous hematologic-oncologic tumors. Sixteen of the patients were male,twelve were female. In syncronous tumors, the most common hematologic malignancy was Non-hodgkın lymphoma (NHL), while the most common oncologic malignancies were thyroid papillary cancer and colon cancer. In metachronous tumors, the most common malignancies were NHL and breast cancer. The median time between diagnosis of metachronous tumors was 49.5 months (8-192 months). The median survival of patients with syncronous malignancies was 19 months (SE=12.19) (95% CI 0-42.89), with metachronous malignancies was 22 months (SE=14.0) (95% CI 0-49.44). There was no statistically significant difference in the comparison of survival curves of patients with syncronous and metachronous malignancies (p=0.382). Oncological malignancies accompanying hematological malignancies are not uncommon. There is no standart treatment for syncronous / metachronous hematologic malignancies. In the presence of syncronous multipl malignancies should be evaluated individually.

show abstract

Section: Castlemancontrasting

confidence: 75%

Section: Castlemanmentioning

confidence: 62%